Why the study?
What is the therapeutic spectrum and safety profile of disopyramide in patients with arrhythmias?
What is the therapeutic spectrum and safety profile of disopyramide in patients with arrhythmias?
Answers are grounded in this paper and cite their sources.
Disopyramide is an effective type I antiarrhythmic but requires caution due to its potential to cause sinus node suppression, proarrhythmia, and heart failure decompensation.
Since disopyramide was introduced 5 years ago, the therapeutic spectrum of this drug in treating patients with ventricular and atrial arrhythmias has been found to be similar to that of the other type I antiarrhythmic drugs, quinidine and procainamide. Disopyramide has the potential to suppress sinus node function and, therefore, must be used cautiously in patients with the sick sinus syndrome. The available data indicate that it can be used safely in patients with bundle branch block and first-degree or type I second-degree atrioventricular block. Disopyramide has been found at times to precipitate ventricular tachycardia or ventricular fibrillation. Because this drug often causes decompensation in patients with congestive heart failure, it must be used very cautiously, if at all, in such patients.
No takes yet. Share an insight, caveat, or question.
Fred Morady (1982) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: